Johnson & Johnson Receives Binding $2.8B Aggregate Value Offer From Fortive Corporation

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Johnson & Johnson announced the obtainment of a binding offer from Fortive Corporation for the acquirement of its Advanced Sterilization Products. ASP is a division of the New Jersey corporation Ethicon, Inc. The offer was for an aggregate value of about $2.8B. ASP, a worldwide leader in inventive infection prevention solutions has a net revenue in 2017 of $775 million.

Advanced Sterilization Products helps healthcare facilities prevent hospital-acquired infections, the leading cause of morbidity and mortality. ASP uses capital, consumables, and software for used in Low-Temperature Terminal Sterilization and High-Level Disinfection of reusable surgical instruments.

There is a 120 day period for the acceptance of the offer. If accepted, the purchase would be predicted to close in early 2019 at the latest.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Happy Friends With Arms Outstretched in City during Winter

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Join us at Vista Partners! It’s FREE to receive email updates.

Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)

NEW BRUNSWICK, N.J., June 6, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Fortive Corporation (NYSE: FTV) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, for an aggregate value of approximately $2.8 billion, consisting of $2.7 bi…..

www.investor.jnj.com

Read Full Article



New Asia Pacific Headquarters for Johnson & Johnson in Singapore

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Johnson & Johnson recently opened a new Asia Pacific Headquarters in Singapore’s Science Park. The new headquarters is characterized by a cutting-edge design lab, a leadership lab, as well as the company’s first international Johnson & Johnson Human Performance Institute.

With the Asia Pacific region being home to half the world’s population and nearly 80% of that region not having access to healthcare, Johnson & Johnson believes it has a responsibility as the world’s largest healthcare company to take on this challenge to bring accessible and affordable healthcare to this region.

The three new facilities located in the Singapore Science Park will allow Johnson & Johnson to find an innovative way to work with the regions government bodies, healthcare agencies, and academic institutions to bring training, classes, and products to the Asia Pacific region.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Marina Bay Sands, Singapore

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Join us at Vista Partners! It’s FREE to receive email updates.

Johnson & Johnson Opens a New Asia Pacific Headquarters

Located in Singapore’s Science Park, Johnson & Johnson?s new regional headquarters will feature a cutting-edge Design Lab, Leadership Lab and the company’s first international Johnson & Johnson Human Performance Institute. Learn more…

www.jnj.com

Read Full Article



J&J Reports Q1 Results & Beats Estimates

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Johnson & Johnson, who reported earnings on April 14, 2018, beat analysts’ estimates of $2.029 earnings/share with $2.06. The company’s sales for Q1 increased 12.6% from 2017 with $20 billion and saw an increase across the board in all sales departments. Net earnings were reported at $4.4 billion for the Q1 this year, and the adjusted net earnings came in at $5.6 billion, which was an 11.8% increase from 2017.

“We are pleased with the strong and consistent performance delivered by our colleagues around the world, demonstrated by our sales and EPS growth in the first quarter. Our Pharmaceutical business continues to deliver robust growth and we are pleased with the improvement in our Consumer business. In our Medical Devices businesses, we have areas of leadership and continue to make investments and portfolio choices to improve performance. The U.S. tax legislation passed late last year is creating the opportunity for us to invest more than $30 billion in R&D and capital investments in the U.S. over the next four years, which is an increase of 15%.” -said Alex Gorsky, Chairman, and Chief Executive Officer.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Lemonade Juice Filled White Ceramic Cup With Saucer

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Join us at Vista Partners! It’s FREE to receive email updates.

Johnson & Johnson Reports 2018 First-Quarter Results:

NEW BRUNSWICK, N.J., April 17, 2018, /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced sales of $20.0 billion for the first quarter of 2018, an increase of 12.6% as compared to the first quarter of 2017. Operational sales results increased 8.4% and the positive impact of currency was 4.2%. Domestic sales i…..

www.investor.jnj.com

Read Full Article



The Dow 30 Beats, Meets, Misses & Scheduled Reports For Current Q1 Earnings Season (Updated 5-17-18)

The Dow 30 Companies have completed another round of earnings report and the vast majority surpassed/or met expectations while only four missed which were Nike (NKE), JPMorgan (JPM), Exxon Mobil (XOM), Home Depot (HD).

The rundown of the Dow 30 beats, meets and misses are in the list below:

  • Nike (NKE) reported earnings on 3/22/2018, & missed estimates of $.555/share.
  • JPMorgan (JPM) reported earnings on 4/13/2018 of $2.37, & missed estimates of $2.92/share.
  • Goldman Sachs (GS) reported earnings on 4/17/2018 of $6.95, & beat estimates of $5.75/share.
  • Johnson & Johnson (JNJ) reported earnings on 4/17/2018 of $2.06, & beat estimates of $2.029/share.
  • UnitedHealth (UNH) reported earnings on 4/17/2018 of $3.04, & beat estimates of $2.968/share.
  • IBM (IBM) reported earnings on 4/17/2018 of $2.45, & beat estimates of 2.415/share.
  • American Express (AXP) reported earnings on 4/18/2018 of $1.86, & beat estimates of $1.747/share.
  • General Electric (GE) reported earnings on 4/20/2018 of $.16, & beat estimates of $.12/share.
  • Procter & Gamble (PG) reported earnings on 4/20/2018 of $1.00 on expectations of $1.002 per share.
  • Caterpillar (CAT) reported earnings on 4/24/2018 of $2.82, & beat estimates of $2.169/share.
  • Coca-Cola (KO) reported earnings on 4/24/2018 of $.47, & beat estimates of $.464/share.
  • 3M (MMM) reported earnings on 4/24/2018 of $2.50, & beat estimates of $2.525/share.
  • United Technologies (UTX) reported earnings on 4/24/2018 of $1.77, & beat estimates of $1.544/share.
  • Verizon (VZ) reported earnings on 4/24/2018 of $1.17, & beat estimates of $1.107/share.
  • Boeing (BA) reported earnings on 4/25/2018 of $3.64, & beat estimates calling for $2.637/share.
  • Visa (V) reported earnings on 4/25/2018 of $1.11, & beat estimates of $1.058/share.
  • Intel (INTC) reported earnings on 4/26/2018 of $.87, & beat estimates of $0.765/share.
  • Microsoft (MSFT) reported earnings on 4/26/2018 of $0.95, & beat estimates of $.892/share.
  • Chevron (CVX) reported earnings on 4/27/2018 of $1.90, & beat estimates of $1.423/share.
  • Exxon Mobil (XOM) reported earnings on 4/27/2018 of $1.09, & missed estimates of $1.179/share.
  • McDonald’s (MCD) reported earnings on 4/30/2018 of $1.72, & beat estimates of $1.706/share.
  • Merck (MRK) reported earnings on 5/1/2018 of $1.05, & beat estimates of $1.004/share.
  • Pfizer (PFE) reported earnings on 5/1/2018 of $0.77, & beat estimates of $0.757/share.
  • Apple (AAPL) reported earnings on 5/1/2018 of $2.73,  & beat estimates of $2.729/share.
  • Dow DuPont (DWDP) reported earnings on 5/3/2018 of $1.12/share, & beat estimates of $1.10/share.
  • Disney (DIS) reported earnings on 5/8/2018  of $1.84/share, & beat estimates of $1.73/share.
  • Home Depot (HD) reported earnings on 5/15/2018 of $2.08/share, & missed estimates of $2.10/share.
  • Cisco (CSCO) reported earnings on 5/16/2018 $.66,  meeting estimates of $.664/share.
  • Wal-Mart (WMT) reported earnings on 5/17/2018 of $1.14, meeting estimates of $1.142/share.

Vista’s Coverage Universe spans the Dow 30, International and Select Emerging Growth Companies & Now “Your Picks”, where we have begun to selectively add those companies/ideas that we are receiving from our brilliant & growing worldly followers that include, tenured heads of industry, innovators, experts of all kinds, board members, buy-side and sell-side analysts, portfolio managers, family office heads, and active investors across all sectors.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Learn More About The AACR Annual Meeting 2018: “Driving Innovative Cancer Science to Patient Care”

The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers and increase public understanding of cancer.

Currently, AACR is holding its AACR Annual Meeting for 2018 in Chicago, Illinois (April 14-18, 2018). This event is one of the main international oncology events highlighting the best cancer science and medicine from institutions all over the world. This years’ Annual Meeting is called “Driving Innovative Cancer Science to Patient Care.” Scientists are harnessing the power of mathematics, engineering, and artificial intelligence to diagnose cancer at an earlier stage. They are also concentrating their efforts on cancer in minorities and the medically underserved, working to eliminate the persistent disparities in cancer outcomes. All of these developments are reflected in the theme.

Four companies under coverage at Vista Partners that have businesses with concerns that relate directly or indirectly to cancer are as follows: Atossa Genetics (ATOS),  Health Insurance Innovations (HIIQ), Johnson & Johnson (JNJ), Merck (MRK) & Pfizer (PFE). Please visit our Coverage section to learn more today.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

 




“Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18

Vista Partners has published “Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & Now “Your Picks”, where we have begun to selectively add those companies/ideas that we are receiving from our brilliant & growing worldly followers that include, tenured heads of industry, innovators, experts of all kinds, board members, buy-side and sell-side analysts, portfolio managers, family office heads, and active investors across all sectors.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




J&J Vision Announces “First of Its Kind” Contact Lenses

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

With the clearance from the U.S. Food and Drug Administration, Johnson & Johnson Vision has announced its first of its kind contact lens ACUVUE OASYS® with Transitions® Light Intelligent Technology™ . The new contact lenses give the wearer vision correction as well as a dynamic photochromic filter that works to constantly balance the amount of light that enters the eye. The contact lenses can quickly and smoothly adjust from clear to dark in a change of light conditions and exposure. They feature a blue filtering light and block UV rays.

With its automatic adjusting capabilities, the ACUVUE OASYS® with Transitions® Light Intelligent Technology™ assists the human eye in managing all different types of lighting situations and brightness intensities all day long.

Johnson & Johnson Vision’s partnership with Transitions Optical works to blend the strengths of each company. With ACUVUE®, the Johnson & Johnson brand, as the world leader in contacts, and Transitions Optical as the leading provider of smart adaptive lenses, the companies are coming together to research and develop the very best-in-class innovative vision care.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Join us at Vista Partners! It’s FREE to receive email updates.

 

Read the original story here.




Wall Street Journal Reports Bayer’s Acquisition of Monsanto Approved by The Justice Department

According to those familiar with the matter, the Justice Department has allowed Bayer AG’s $60 billion acquisition of Monsanto Co. The decision came after the two companies agreed to sell off their additional assets in order to secure government antitrust approval. With this breakthrough, the Justice Department’s concerns about the deal were addressed and the merger can continue to move forward.

In September of 2016, the two major agriculture companies announced their deal to create a new agricultural powerhouse. Bayer AG is a German company that plays a leading role in the pesticide industry, and Monsanto, headquartered in St. Louis, MO, is a leader in crop genetics

Although conditionally approved by the European Union last month, the U.S. Justice Department voiced major concerns on how the merger could have a different competitive effect on both farmers and consumers, especially in the genetically modified seed market.

Bayer’s purchase of Monsanto is the third of recent agriculture megadeals. DowChemical Co. and DuPont Co merged last year and Syngenta AG completed its deal with China National Chemical Corp.

These megadeals have increased farmers’ worries about their effects on prices and farm incomes, and have urged antitrust enforcers to block the deals. Farmer’s voice concern that with less global competition, prices on crucial farm supplies will raise and there will be fewer choices for the farmers.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Justice Department to Allow Bayer?s Acquisition of Monsanto After Company Concessions

The Justice Department will allow Bayer?s megadeal to acquire Monsanto after the companies pledged to sell off additional assets to secure government antitrust approval…

www.wsj.com

Read Full Article



“Where’s That Bunny Headed?”

Vista Partners has published “Where’s That Bunny Headed?” Vista Partners Weekly Market Update 3-31-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Caruso Announces Retirement From Johnson & Johnson

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Dominic J. Caruso, Executive Vice President, Chief Financial Officer of Johnson & Johnson has announced his decision to retire in September 2018. Caruso has been CFO of the company since 2007. Johnson & Johnson finished three of its largest acquisitions under Caruso: Actelion, Synthes, and Pfizer Consumer Health. He also played a key role in the driving grown and the company’s allocation strategies and created a top-notch Talent Development Program.

“During his nearly 12 years as CFO, Dominic provided Credo-based leadership and financial stewardship through the economic downturn and was instrumental in helping the Company deliver significant gains over the past five years.  Dominic made a big impact inside our company, and he is well-respected throughout our industry. We wish Dominic, his wife, Debbie, and their family the very best in the years ahead.” – Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson.

Caruso’s successor will be Joseph Wolk, Vice President of Johnson & Johnson Investor Relations, effective July 1, 2018. Caruso and Wolk will work closely together throughout the six-month transition.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson

NEW BRUNSWICK, N.J., March 20, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that Dominic J. Caruso, Executive Vice President, Chief Financial Officer, has elected to retire in September 2018 after a distinguished 19-year career with the Company.  Caruso was named CFO in 2007, and served as CFO longer than anyone in…..

www.investor.jnj.com

Read Full Article